StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Allergan (AGN) Says FDA Accepts sBLAs for BOTOX for Pediatric Patients with Upper and Lower Limb Spasticity
March 7, 2019 8:02 AM
Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Allergan (AGN) Reports FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
March 11, 2019 7:32 AM
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity
March 7, 2019 8:00 AM